Literature DB >> 21993200

Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells.

Ellen L Crossley1, Fatiah Issa, Alana M Scarf, Michael Kassiou, Louis M Rendina.   

Abstract

New 1,2-closo- and 7,8-nido-carboranylpyrazolopyrimidines bind to the translocator protein (TSPO) with high affinity, providing the first evidence of a unique two-site binding profile for the closo-carborane derivative. The boron-rich compounds can also deliver boron to human glioma cells far more effectively than clinical agents used in boron neutron capture therapy (BNCT).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993200     DOI: 10.1039/c1cc14587h

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  4 in total

Review 1.  The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity.

Authors:  Shane M Wilkinson; Hendra Gunosewoyo; Melissa L Barron; Aurelie Boucher; Michelle McDonnell; Peter Turner; Daniel E Morrison; Maxwell R Bennett; Iain S McGregor; Louis M Rendina; Michael Kassiou
Journal:  ACS Chem Neurosci       Date:  2014-04-03       Impact factor: 4.418

2.  Dodecaborate Conjugates Targeting Tumor Cell Overexpressing Translocator Protein for Boron Neutron Capture Therapy.

Authors:  Yoshihide Hattori; Miki Ishimura; Youichirou Ohta; Hiroshi Takenaka; Shinji Kawabata; Mitsunori Kirihata
Journal:  ACS Med Chem Lett       Date:  2021-12-01       Impact factor: 4.345

3.  Modulation of γ-Secretase Activity by a Carborane-Based Flurbiprofen Analogue.

Authors:  Stefan Saretz; Gabriele Basset; Liridona Useini; Markus Laube; Jens Pietzsch; Dijana Drača; Danijela Maksimović-Ivanić; Johannes Trambauer; Harald Steiner; Evamarie Hey-Hawkins
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

4.  Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy.

Authors:  Marcos Couto; Catalina Alamón; María Fernanda García; Mariángeles Kovacs; Emiliano Trias; Susana Nievas; Emiliano Pozzi; Paula Curotto; Silvia Thorp; María Alejandra Dagrosa; Francesc Teixidor; Clara Viñas; Hugo Cerecetto
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.